1. Scrip
  2. >>Business

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Broad Alliance Involves New Entities

 
• By Ian Haydock

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

businessman and businesswoman are exchanging document or contract
Multi-Vant Deal Finalized • Source: Shutterstock

Following their early September surprise announcement of a broad alliance, Sumitomo Dainippon Pharma Co. Ltd. (SDP) and Roivant Sciences Inc. have now finalized and fleshed out their $3bn deal under which the Japanese firm will acquire stakes in up to 11 "vant" companies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business